ABBVIE INC

AbbVie’s Epcoritamab/Lenalidomide combo hits Phase 3 success in relapsed DLBCL, while a $10 M milestone with Nxera boosts its neuroscience pipeline—paving the way for 2026‑27 launch and new revenue streams.

AbbVie’s Phase‑3 epcoritamab + lenalidomide study shows a clear PFS win in relapsed/refractory DLBCL, offering a safe, fixed‑duration, cost‑effective alternative to CAR‑T and chemo‑immunotherapy.

AbbVie’s $109 billion Apogee Therapeutics deal boosts gene‑therapy pipelines, offsets patent cliffs, and strengthens its market moat, positioning it for sustained growth in 2026.

AbbVie’s FDA approval of SKYRIZI® for pediatric psoriasis and psoriatic arthritis, with weight‑based dosing and a new AD candidate, boosts its immunology portfolio and investor appeal.

AbbVie’s new pediatric SKYRIZI approval and $10.9 bn Apogee acquisition give the drugmaker a fresh, high‑growth immunology pipeline that buffers patent cliffs and targets premium pricing in psoriasis, AD and pediatrics.

AbbVie’s modest share‑price rise reflects its robust cash flow, dividend yield of 4.8%, and strategic R&D to beat biosimilar competition and secure payer value.

AbbVie’s acquisition of Apogee Therapeutics and new approvals for Skyrizi, Maviret, and Boey® boost its portfolio across atopic dermatitis, psoriasis, and aesthetic medicine, offering faster, safer treatments and expanding market reach.

AbbVie’s $11 billion acquisition of Apogee Therapeutics boosts its anti‑inflammatory pipeline, positioning the drugmaker to win market share, curb patent‑cliff risk and drive $200 m EBITDA growth.

AbbVie’s $11 billion bid for Apogee Therapeutics could reshape the biologics market—adding a long‑acting, low‑frequency therapy for inflammatory diseases and boosting AbbVie’s portfolio and patient outcomes.

AbbVie’s CLL14 Phase III results show venetoclax‑obinutuzumab gives eight‑year disease control with fewer side‑effects, reshaping first‑line CLL care.